Dynavax Technologies Corporation [DVAX] stock is down -4.05 while the S&P 500 has fallen -1.66% on Monday, 10/19/20. While at the time of this article, DVAX ATR is sitting at 0.36, with the beta value at 1.14. This stock’s volatility for the past week remained at 8.23%, while it was 6.81% for the past 30-day period. DVAX has fallen -$0.18 from the previous closing price of $4.44 on volume of 2.57 million shares.

On 13, October 2020, Medigen’s COVID-19 Vaccine Combined with Dynavax’s CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October. According to news published on Yahoo Finance, Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that MVC has obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan. The first participant in MVC’s Phase 1 clinical trial was dosed with MVC’s COVID-19 vaccine combined with Dynavax’s CpG 1018 adjuvant at National Taiwan University Hospital in early October. The subsidy will be released at agreed upon milestones in the total amount of up to NT$ 472 million (US$ 16.4 million). The grant received by MVC was earmarked by the Taiwan government for purposes of research and development of a locally produced COVID-19 vaccine.

Analyst Birdseye View:

The most recent analyst activity for Dynavax Technologies Corporation [NASDAQ:DVAX] stock was on August 03, 2020, when it was Reiterated with a Buy rating from H.C. Wainwright, which also raised its 12-month price target on the stock from $12 to $14. Before that, on August 07, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $12. On June 15, 2020, Evercore ISI Initiated an Outperform rating and boosted its price target on this stock to $14. On October 18, 2019, H.C. Wainwright Initiated a Buy rating and increased its price target to $13. On July 11, 2019, Cantor Fitzgerald Upgrade an Overweight rating and increased its price target to $20. On February 27, 2019, Cantor Fitzgerald Reiterated an Overweight rating and boosted its amount target on this stock to $28. On May 10, 2018, JP Morgan Upgrade an Overweight rating. On March 08, 2018, Cantor Fitzgerald Reiterated an Overweight rating and improved its amount target to $27.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.80 and a peak of $12.44. Right now, according to Wall Street analyst the average 12-month amount target is $15.33. At the most recent market close, shares of Dynavax Technologies Corporation [NASDAQ:DVAX] were valued at $4.26.

FUNDAMENTAL ANALYSIS

Dynavax Technologies Corporation [NASDAQ:DVAX] most recently reported quarterly sales of 2.67 billion, which represented growth of -67.50%. This publicly-traded organization’s revenue is $152,463 per employee, while its income is -$660,606 per employee. This company’s Gross Margin is currently 51.90%, its Pretax Margin is -433.29, and its Net Margin is -433.29. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -62.29, -427.72, -60.86 and -78.52 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 96.36 and the whole liability to whole assets at 78.65. It shows enduring liability to the whole principal at 95.03 and enduring liability to assets at 0.78 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 4.16 points at 1st support level, the second support level is making up to 4.07. But as of 1st resistance point, this stock is sitting at 4.41 and at 4.57 for 2nd resistance point.

Dynavax Technologies Corporation [DVAX] reported its earnings at -$0.53 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.24/share signifying the difference of -0.29 and -120.80% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.15 calling estimates for -$0.31/share with the difference of 0.16 depicting the surprise of 51.60%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Dynavax Technologies Corporation [NASDAQ:DVAX] is 5.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.85. Now if looking for a valuation of this stock’s amount to sales ratio it’s 11.70 and it’s amount to book ratio is 57.87.

Insider Stories

The most recent insider trade was by Janssen Robert, Senior Vice President, and it was the sale of 50000.0 shares on Jul 17. Hack Andrew A. F., the Director, completed a purchase of 1.0 million shares on May 27. On May 19, Janssen Robert, Senior Vice President, completed a sale of 15000.0 shares.